Sandro Rodriguez

Not all scientists wear white coats...

[Sandro Rodriguez @Sandroppa]

Latest data from @SCSMonash @PeterEbeling2 team https://t.co/ktHGZ9tMit We show that #alendronate & #zoledronate have cardiac effects but less so than #teriparatide which may have some protective benefit. Validation required in better characterised clinical cohorts

[ANZBMS @ANZBMSoc]

'Major adverse cardiovascular event rates in unselected women with and without fracture during treatment with clodronate or placebo: secondary analysis of a randomised controlled trial' - Alexander J. Rodriguez https://t.co/J5Ub8zPBNX #ESASRBANZBMS @ESASRB /9

[Sandro Rodriguez @Sandroppa]

@JoyYWu @purton_louise @michbal19 @NatalieASims @PeterEbeling2 @EndoSocAus @ANZBMSoc Looking forward to having you down under in RADelaide

[Sandro Rodriguez @Sandroppa]

@ANZBMSoc @EndoSocAus @healthybones_au Responsibility also falls on drug companies to properly educate front line prescribers and provide tools on how to communicate risks-benefits to patients

[Sandro Rodriguez @Sandroppa]

An interesting on stopping #denosumab b/c rare side effects by @RACGP Vic Chair “whomever is asking the patient to stop the drug needs to take responsibility for giving that information” https://t.co/NHyjc9LCWi

[Sandro Rodriguez @Sandroppa]

@ANZBMSoc @EndoSocAus One wonders about the (mis)information patients receive from sources not across the literature and not able to place it in the clinical context @healthybones_au

[Osteoporosis IOF @iofbonehealth]

Healthy bones are at the core of our well-being, mobility and independence. Today on #WorldOsteoporosisDay we urge people of all ages to protect their bone health by taking early action for #osteoporosis prevention. https://t.co/v19WyJMsWQ

[Sandro Rodriguez @Sandroppa]

@PeterEbeling2 @ASBMR @SCSMonash Another triumph! Well done Peter 🎉

[Tuan V. Nguyen @nguyen_osteo]

In older adults, the risk of death is often higher than the risk of fracture. But does accounting for the competing risk of death impact fracture risk assessment? Our findings indicate it does not—at least in the short term.

https://t.co/4Asl16i69a

[Annals of Int Med @AnnalsofIM]

Most read at Annals: Pharmacologic Treatment of Primary #Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From @ACPIMPhysicians
https://t.co/wMg63aG4rB

[Sandro Rodriguez @Sandroppa]

@VinceRugari I see what you’re saying Vince. When Antonio Conte took the Inter job, that hurt juventini. Same with Marotta taking the SD role.

[Málaga CF @MalagaCF]

🤍 𝐋𝐎 𝐇𝐈𝐂𝐈𝐌𝐎𝐒 💙

¡Estamos de vuelta, @LaLiga2! 🫡

[Málaga CF @MalagaCF]

▶️ 𝗙𝗜𝗡𝗔𝗟

#NàsticMálaga

[Sandro Rodriguez @Sandroppa]

@MedStudent_007 @NHSEngland “Generalist”? Weren’t they also “specialists”?

[Sandro Rodriguez @Sandroppa]

@Dineshh_BhD Sit back and enjoy! This is the cyber version of watching a comet pass. We’ll all be reminiscing about this day in the future.

[Sandro Rodriguez @Sandroppa]

@drkamikhan123 Is there a book with all these wonderful charts?

[Sandro Rodriguez @Sandroppa]

@MWeintraubMD @PeterEbeling2 @SCSMonash Important practice points!

[Sandro Rodriguez @Sandroppa]

@Medical_MD1 “Client” this is surely Made in USA™️

[Sandro Rodriguez @Sandroppa]

@LachMcMillan @rbarbosa91 Genuinely interested in the outcome of this study 👀

[Michael Weintraub, MD @MWeintraubMD]

🚨New Trial Results🚨

Semaglutide improves chronic kidney disease outcomes by 24% in pts with type 2 diabetes and CKD, in @NEJM today.

⬇️29% cardiovascular death
⬇️18% cardiovascular events
⬇️20% all-cause mortality
Slower GFR decline 1.16 vs 1.73 / year
https://t.co/WkGgnl7FIO